HB0085 / Zhejiang Huahai Pharma, Huaota Biopharm, Huabo Biopharmaceutical Technology - LARVOL DELTA

A bispecific antibody-drug conjugate targeting protein tyrosine kinase 7 and fibroblast activation protein alpha simultaneously acts on tumor cells and the tumor microenvironment (AACR 2026) - "Furthermore, when combined with the bispecific antibody HB0025 (targeting PD-L1/VEGF), the antitumor activity of HB0085 was significantly enhanced. These results position HB0085 as a promising therapeutic candidate for a range of solid tumors."

ADC • Biomarker • Bispecific • Tumor cell • Tumor microenvironment • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CAFs • FAP • PTK7